Display options
Share it on

Chest. 2021 Dec;160(6):e609-e611. doi: 10.1016/j.chest.2021.07.031.

Intrapleural Hyaluronidase in Viscous Malignant Mesothelioma Pleural Effusion.

Chest

Chuan T Foo, Anna Paterson, Adam Duckworth, Jurgen Herre

Affiliations

  1. Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England. Electronic address: [email protected].
  2. Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England.
  3. Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England.

PMID: 34872672 DOI: 10.1016/j.chest.2021.07.031

Abstract

Malignant pleural effusion is common in mesothelioma. We report a case of viscous recurrent malignant mesothelioma pleural effusion. The viscosity was due to the presence of hyaluronic acid and resulted in prolonged drainage time. The use of intrapleural hyaluronidase significantly reduced fluid viscosity and drainage duration. No adverse reactions were noted. This novel case highlights the feasibility and safety of the use of intrapleural hyaluronidase in the management of hyaluronic acid-rich viscous malignant pleural effusion.

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Keywords: hyaluronic acid; hyaluronidase; malignant pleural effusion; mesothelioma; viscous pleural effusion

Publication Types